Considering the coexistence of oxidative stress and inflammation in various cardiac diseases, we investigated the ability of the IL-6 inhibitor to restore altered cardiomyocyte stiffness at higher sarcomere lengths and found comparable results upon the treatment. This evidence concerns the gene IL6 and heart disorder.